HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
Stocks · News reference
Zenas BioPharma To Present New Data From Phase 3 INDIGO Trial Evaluating Obexelimab In IgG4-RD At 6th International Symposium On IgG4-Related Disease, And ACR Convergence 2026
– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –– Additional analyses will assess glucocorticoid-associated toxicity and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
Zenas BioPharma presented new clinical data for obexelimab at the 6th International Symposium on IgG4-Related Disease. Phase 3 INDIGO open-label extension results showed sustained clinical activity with a 93% probability of remaining flare-free at 12 months, significantly reduced glucocorticoid toxicity compared to placebo, and positive vaccine responses during a treatment-free window. The data supports obexelimab's potential as a steroid-sparing B-cell inhibitor for long-term IgG4-RD management.
Zenas BioPharma Presents New Obexelimab Data In Immunoglobulin G4-Related Disease At 6th International Symposium On IgG4-Related Disease
– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab –– Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically
Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48